NASDAQ:LGND Ligand Pharmaceuticals (LGND) Stock Price, News & Analysis $112.50 -1.95 (-1.70%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$112.52 +0.02 (+0.02%) As of 06/13/2025 06:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Ligand Pharmaceuticals Stock (NASDAQ:LGND) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Ligand Pharmaceuticals alerts:Sign Up Key Stats Today's Range$110.18▼$113.7250-Day Range$96.67▼$115.3952-Week Range$77.53▼$129.90Volume83,330 shsAverage Volume116,608 shsMarket Capitalization$2.17 billionP/E Ratio44.82Dividend YieldN/APrice Target$146.14Consensus RatingBuy Company OverviewLigand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.Read More… Ligand Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks88th Percentile Overall ScoreLGND MarketRank™: Ligand Pharmaceuticals scored higher than 88% of companies evaluated by MarketBeat, and ranked 115th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingLigand Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageLigand Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Ligand Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth114.45% Earnings GrowthEarnings for Ligand Pharmaceuticals are expected to grow by 114.45% in the coming year, from $1.73 to $3.71 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ligand Pharmaceuticals is 44.82, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.29.Price to Earnings Ratio vs. SectorThe P/E ratio of Ligand Pharmaceuticals is 44.82, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.75.Price to Book Value per Share RatioLigand Pharmaceuticals has a P/B Ratio of 2.79. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Ligand Pharmaceuticals' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.92% of the float of Ligand Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverLigand Pharmaceuticals has a short interest ratio ("days to cover") of 10.2, which indicates bearish sentiment.Change versus previous monthShort interest in Ligand Pharmaceuticals has recently increased by 12.84%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLigand Pharmaceuticals does not currently pay a dividend.Dividend GrowthLigand Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.4 / 5Environmental Score-1.57 Percentage of Shares Shorted6.92% of the float of Ligand Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverLigand Pharmaceuticals has a short interest ratio ("days to cover") of 10.2, which indicates bearish sentiment.Change versus previous monthShort interest in Ligand Pharmaceuticals has recently increased by 12.84%, indicating that investor sentiment is decreasing significantly. News and Social Media2.6 / 5News Sentiment0.69 News SentimentLigand Pharmaceuticals has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.89 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Ligand Pharmaceuticals this week, compared to 5 articles on an average week.MarketBeat Follows2 people have added Ligand Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Ligand Pharmaceuticals insiders have bought 617.15% more of their company's stock than they have sold. Specifically, they have bought $1,156,542.00 in company stock and sold $161,270.00 in company stock.Percentage Held by InsidersOnly 7.00% of the stock of Ligand Pharmaceuticals is held by insiders.Percentage Held by Institutions91.28% of the stock of Ligand Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ligand Pharmaceuticals' insider trading history. Receive LGND Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ligand Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address LGND Stock News HeadlinesLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Insider Sells $57,270.00 in StockJune 13 at 8:42 AM | insidertrades.comAndrew Reardon Sells 1,000 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) StockJune 3, 2025 | insidertrades.comThe Robotics Revolution has arrived … and one $7 stock could take off as a result.While practically every popular investment has been swinging wildly these past weeks … Gold has been surging to new record highs. And according to Wall Street's biggest banks, this is just the start … Goldman Sachs is telling clients to "buy gold" to protect from the trade wars and economic uncertainty.June 16, 2025 | Weiss Ratings (Ad)Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives $146.14 Consensus Target Price from AnalystsJune 13 at 1:33 AM | americanbankingnews.comLGND Makes Bullish Cross Above Critical Moving AverageJune 11, 2025 | nasdaq.comLigand Announces 2025 Investor Day in New York CityJune 11, 2025 | globenewswire.comLigand to Ring the Nasdaq Opening Bell on May 19, 2025May 14, 2025 | globenewswire.comLGND: 1Q:25 ResultsMay 12, 2025 | msn.comSee More Headlines LGND Stock Analysis - Frequently Asked Questions How have LGND shares performed this year? Ligand Pharmaceuticals' stock was trading at $107.15 on January 1st, 2025. Since then, LGND shares have increased by 5.0% and is now trading at $112.50. View the best growth stocks for 2025 here. How were Ligand Pharmaceuticals' earnings last quarter? Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) issued its earnings results on Thursday, May, 8th. The biotechnology company reported $1.33 EPS for the quarter, topping analysts' consensus estimates of $1.23 by $0.10. The biotechnology company earned $45.33 million during the quarter, compared to analysts' expectations of $37.84 million. Ligand Pharmaceuticals had a trailing twelve-month return on equity of 4.95% and a net margin of 29.68%. Read the conference call transcript. Who are Ligand Pharmaceuticals' major shareholders? Ligand Pharmaceuticals' top institutional investors include Vanguard Group Inc. (10.66%), Congress Asset Management Co. (3.34%), Stephens Investment Management Group LLC (3.15%) and Chicago Capital LLC (2.88%). Insiders that own company stock include John L Higgins, Todd C Davis, Matthew E Korenberg, John W Kozarich, Andrew Reardon, John L Lamattina, Stephen L Sabba, Octavio Espinoza and Nancy Ryan Gray. View institutional ownership trends. How do I buy shares of Ligand Pharmaceuticals? Shares of LGND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ligand Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ligand Pharmaceuticals investors own include NVIDIA (NVDA), Invesco QQQ (QQQ), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX) and Palo Alto Networks (PANW). Company Calendar Last Earnings5/08/2025Today6/15/2025Next Earnings (Estimated)8/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:LGND CIK886163 Webwww.ligand.com Phone(858) 550-7500Fax858-550-1826Employees80Year FoundedN/APrice Target and Rating Average Stock Price Target$146.14 High Stock Price Target$160.00 Low Stock Price Target$135.00 Potential Upside/Downside+29.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($7.12) Trailing P/E Ratio44.82 Forward P/E Ratio65.03 P/E GrowthN/ANet Income$52.15 million Net Margins29.68% Pretax Margin38.59% Return on Equity4.95% Return on Assets4.39% Debt Debt-to-Equity RatioN/A Current Ratio12.49 Quick Ratio11.81 Sales & Book Value Annual Sales$181.49 million Price / Sales11.96 Cash Flow$4.61 per share Price / Cash Flow24.39 Book Value$40.39 per share Price / Book2.79Miscellaneous Outstanding Shares19,294,000Free Float17,780,000Market Cap$2.17 billion OptionableOptionable Beta0.83 Social Links 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:LGND) was last updated on 6/16/2025 by MarketBeat.com Staff From Our PartnersAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored[First Look] Get in before potential 10X AI announcementsGo for 10X gains from the next big AI announcement — starting as soon as 7 days from now Former floor trade...Masters in Trading | SponsoredBillionaires are piling into this gold investmentBillionaires Are Piling into a Special Gold Investment With record gold prices, everyday Americans are scra...Weiss Ratings | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ligand Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Ligand Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.